FDA Approves Merck’s Enflonsia

The FDA approved Merck’s Enflonsia (clesrovimab-cfor) which is a monoclonal antibody designed to protect infants against respiratory syncytial virus (RSV) disease. Enflonsia can be given to infants during their first RSV season. Merck’s Enflonsia is similar to Sanofi’s Beyfortus. PCA will begin offering Enflonsia to our members through our Merck program when it becomes available to purchase.

Although Enflonsia is a monoclonal antibody and not a vaccine, we anticipate the ACIP will make recommendations on how Enflonsia should be used. Payer coverage typically occurs within a year after ACIP recommendations are published in the MMWR. We will provide additional information as it becomes available.

To learn more, click here to read Merck’s news release.

FDA Approves Moderna’s new COVID-19 Vaccine mNEXSPIKE

This fall PCA hopes to offer members the opportunity to purchase Moderna’s new COVID-19 vaccine mNEXSPIKE for their patients 65 years and older and high-risk individuals aged 12-64 years. According to Moderna’s press release, this new COVID-19 vaccine “showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older, and in a descriptive sub-group analysis, a 13.5% higher rVE in adults aged 65 and older” compared to Spikevax, Moderna’s original COVID-19 vaccine.

Once a new vaccine has been approved by the FDA, it is reviewed by the ACIP. This committee will make recommendations on how this vaccine should be used. Payer coverage typically occurs after ACIP recommendations are published in the MMWR. We will provide additional information as it becomes available.

To learn more, click here to read Moderna’s news release.

Penbraya Broadcast Hosted on June 16, 2025

Pfizer is offering a virtual broadcast on the risk of invasive meningococcal disease in adolescents and the role of a pentavalent MenABCWY vaccine. During the broadcast, experts will:

Detail the burden of invasive meningococcal disease and the recent rise in cases in the United States
Provide insights on how substantial gaps in meningococcal vaccination leave the majority of older adolescents at risk
Review the latest ACIP recommendations for meningococcal vaccination
Familiarize you with the robust immunogenicity provided by PENBRAYA against 5 disease-causing meningococcal serogroups as shown in clinic trials
Discuss clinical considerations for how PENBRAYA, as a combination vaccine, may help simplify the meningococcal vaccination schedule

The virtual broadcast is offered two times on Monday, June 16^th 12:00 – 1:00 PM (ET) or 3:00 – 4:00 PM (ET). For more details, view the flyer here and click here to sign up.

How to Return COVID-19 and Flu Vaccines — 2024-2025 Season

If you have COVID-19 or flu vaccine doses left from this past season, now is the time to return them. We’ve listed the instructions for each manufacturer below. Please note that each manufacturer has a specific deadline. Once you have returned your vaccines, please allow 4-6 weeks for processing time.

COVID-19 Vaccines

Moderna –

If customer purchased Moderna COVID-19 vaccine through www.ModernaDirect.com, please click here for directions on how to obtain a Return Authorization (RA) from Inmar. Once you receive the RA from Inmar, the customer is responsible for shipping the vaccine to Inmar. It does not need to be refrigerated. Returns must be shipped back prior to August 31, 2025.

If customer purchased the Moderna COVID-19 vaccine through a distributor, please contact the distributor for information on how to return the unused COVID-19 vaccine. Each distributor will have its own return policy and return deadlines.

Pfizer –

Please click here for directions on how to return Pfizer COVID-19 vaccines. All returns must be received prior to September 15, 2025.

Flu Vaccines

Sanofi –

Customers are eligible to return up to 15% of their shipped influenza reservation by presentation. Returns exceeding the allowable thresholds will receive a federal excise tax credit only. To get started, log in to www.VaccineShop.com and follow these simple steps:

Once logged into www.VaccineShop.com, navigate to the Returns Tab.
Select “Create a Return” from the dropdown menu.
Enter product details, quantity in doses, number of boxes requiring Return Authorization labels, and account user’s email address.
Click “Submit” to complete your Return Authorization.
Check the status of your return by clicking the “Return History” tab.

To view the quick guide, please click here. For additional assistance, you can also reference the many resources available, including VaccineShop’s Returns Help Center which has many short instructional videos such as: Help Me With My Return, What’s My Return Status Mean? or the VaccineShop Returns Quick Guide.

Please note all eligible influenza returns must be physically received by Inmar no later than July 31, 2025, otherwise credit will be given for federal excise tax only. We encourage you to send your return immediately upon expiration for timely processing.

If you have any questions or are unable to process returns on VaccineShop.com, please contact me Sanofi’s Customer Service, 1-800-VACCINE (822-2463).

Seqirus –

Customers must complete the return requests by June 15, 2025, after which the product must be received by Inmar no later than June 28, 2025.

If customer have a direct account with Inmar, they can log into their www.flu360.com account. On the right side of the screen, click on “Orders” then “Returns.” Please click here for Influenza Vaccine Returns FAQ and checklist.

If customer does not have a direct account with Inmar, please click here to download the return form.

If you have any questions, please email Amy Bullock at abullock@primarycarealliance.com or call her at (801) 369-3933